Evonik's Standalone Case Faces Its First Public Test in Frankfurt
Published on 11/22/2026 at 14:22 | Editorial boerse-global.deEvonik's shareholders have spent the past week recalibrating what the chemicals maker is worth on its own. The answer will get its first public airing on 23 November 2026, when the company appears at the Deutsches Eigenkapitalforum in Frankfurt.
That date matters because BASF walked away from its takeover pursuit on Thursday, having had two unsolicited all-cash offers rebuffed by Evonik's management. The final proposal stood at 24 euros a share. BASF said it would not go higher, and according to Reuters, the Ludwigshafen-based group saw no room to raise its price given the prospects and risks of a standalone Evonik. The stock closed Friday at €18.18, extending a decline that had already seen it shed 16% on Thursday.
The gap between that €18.18 close and the abandoned 24-euro bid is the number now framing every conversation about the stock. It is not, however, a reliable measure of what Evonik is worth by itself — a point the market has yet to settle.
A Rating Reset, Not an Operating Warning
Oddo BHF moved Evonik to "Neutral" from "Outperform" on Friday and trimmed its price target to 19 euros from 22. The new marker sits below what BASF last offered, a clear signal that the French broker has stripped the takeover premium out of its valuation. What the downgrade does not do is say anything about Evonik's underlying business — it reflects the disappearance of a bid, not a deterioration in operations.
Interim chief executive Claus Rettig said after BASF's withdrawal that the company would focus on its standalone development. That commitment now needs substance. Investors will want more than a headline target: they need to see which operational levers management intends to pull, and how progress on them can be tracked quarter by quarter.
Should investors sell immediately? Or is it worth buying Evonik?
A useful distinction would be between improvements Evonik can control itself and those that depend on more favourable market conditions. The sharper that line, the easier it becomes to judge how durable the earnings story is when the environment turns less forgiving.
What Would Justify a Re-rating
Reuters reported on Wednesday, citing two people familiar with Evonik, that a higher BASF bid alone would not have secured support for a deal — a convincing industrial rationale would also have been required. The same logic cuts the other way for the standalone case: rejecting an offer does not by itself prove that independence is worth more. That case has to be built on how the value would actually be generated.
If Evonik can lay out its earnings outlook concretely enough for investors to verify the milestones later, a re-rating is conceivable without any approach to the old offer price. It would rest on greater confidence in expected profits rather than on hopes of another bidder emerging. Whether that confidence holds would then be tested by actual business performance.
The risk is the mirror image: a share price that looks cheap against the BASF bid but lacks the earnings prospects to back that view. If management cannot tie its expected progress to traceable operational steps, the discount to the abandoned offer becomes a value trap rather than catch-up potential.
The Overhang From RAG-Stiftung
Ownership is a separate question from earnings, and it deserves separate treatment. RAG-Stiftung reaffirmed on Friday its intention to reduce its roughly 43% stake step by step to 25.1%. That is a stated goal, not a completed sale, and it says nothing about future profitability.
The foundation also expressed regret that no in-depth exploratory talks had taken place between the two boards. IG BCE, for its part, urged RAG-Stiftung to anchor that 25.1% minimum holding permanently in its statutes and to contribute more to growth and investment at Evonik going forward.
Frankfurt as the Proving Ground
All of this puts unusual weight on a routine investor conference. Evonik's participation is confirmed, but it is not yet a signal of new guidance. What the market will be listening for is whether management can make the standalone earnings case tangible — a verifiable statement about profit development would be worth more to investors than any comparison with the bid that got away.
If the assumptions prove too optimistic, or the expected advances fail to materialise, the cheaper-looking scenario loses its foundation and the old offer price offers no dependable anchor. Should Evonik instead deliver a credible, checkable roadmap in Frankfurt, the stock has a case that does not depend on a buyer's interest.
Ad
Evonik Stock: New Analysis - 22 November
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
